Navigation Links
GW Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
Date:11/18/2013

LONDON, Nov. 18, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Thursday, 21 November, 2013 at 8:00 a.m. GMT. The conference will be held at the Waldorf Hilton Aldwych, London.

A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional clinical-stage cannabinoid product candidates targeting epilepsy (including an orphan pediatric epilepsy program), Type 2 diabetes, ulcerative colitis, glioma and schizophrenia. For further information, please visit www.gwpharm.com.


'/>"/>
SOURCE GW Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
2. RXi Pharmaceuticals Corporation and Ethicor Ltd. Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
3. Isis Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-APO(a) Rx Produces Significant Reductions in Lp(a) Levels
4. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
5. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
6. ANI Pharmaceuticals To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
7. Ampio Pharmaceuticals to Present at Upcoming Investor Conference
8. DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
9. Intercept Pharmaceuticals Reports Third Quarter 2013 Financial Results
10. Isis Pharmaceuticals Earns $1.5M from the Advancement of the Phase 2 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
11. Actinium Pharmaceuticals Appoints Richard Steinhart As New Independent Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):